46 results on '"Garmany, Ramin"'
Search Results
2. Proteomic and phosphoproteomic analyses of myectomy tissue reveals difference between sarcomeric and genotype-negative hypertrophic cardiomyopathy
3. Abstract 17344: Risk Factors for Disease Severity in Cardiac Laminopathy
4. Abstract 17329: Histone Modifications Regulate Hypertrophy Pathways in Obstructive Hypertrophic Cardiomyopathy
5. Abstract 15291: Early Outcomes With Left Cardiac Sympathetic Denervation for Medically Refractory Idiopathic Ventricular Fibrillation
6. Histone Modifications and miRNA Perturbations Contribute to Transcriptional Dysregulation of Hypertrophy in Obstructive Hypertrophic Cardiomyopathy
7. A Multi-Omics Atlas of Sex-Specific Differences in Obstructive Hypertrophic Cardiomyopathy
8. Temporal Association Between Vaping and Risk of Cardiac Events
9. Return-to-Play for Athletes With Long QT Syndrome or Genetic Heart Diseases Predisposing to Sudden Death
10. Abstract 13153: Proteomic Differences in Sarcomere Positive HCM May Explain More Severe Clinical Differences
11. Abstract 13141: Age of Onset and Clinical Outcomes in RBM20-Mediated Arrhythmogenic Dilated Cardiomyopathy
12. Abstract 12736: Cardiac Fludeoxyglucose-18 Positron Emission Tomography in Genotype-Positive Arrhythmogenic Cardiomyopathy
13. Clinical and functional reappraisal of alleged type 5 long QT syndrome: Causative genetic variants in the KCNE1-encoded minK β-subunit
14. BS-452759-1 SPATIAL CLUSTERING ANALYSIS HIGHLIGHTS DISEASE-SPECIFIC 3-DIMENSIONAL DISTRIBUTION OF PATHOGENIC VARIANTS IN THE -ENCODED NAV1.5 CARDIAC SODIUM CHANNEL
15. PO-02-142 MIRNA DOWN-REGULATE HYPERTROPHY AND INFLAMMATORY PATHWAYS IN THE TRANSCRIPTOME OF HYPERTROPHIC CARDIOMYOPATHY MYECTOMY TISSUE
16. BS-452758-3 SUPPRESSION-REPLACEMENT GENE THERAPY FOR -MEDIATED CARDIOMYOPATHIES
17. PO-04-143 CARDIOVASCULAR OUTCOMES IN -MEDIATED CARDIAC LAMINOPATHY: THE MAYO CLINIC EXPERIENCE
18. Cardiac fludeoxyglucose-18 positron emission tomography in genotype-positive arrhythmogenic cardiomyopathy
19. Clinical course of patients with hypertrophic cardiomyopathy away from tertiary referral care
20. RASopathy-Associated Cardiac Hypertrophy
21. Multi-Omic Architecture of Obstructive Hypertrophic Cardiomyopathy
22. Cardiopulmonary Exercise Testing in Athletes With Hypertrophic Cardiomyopathy
23. Hypertrophic Cardiomyopathy Polygenic Risk Score Correlates with Genotype but Not Clinical Severity.
24. PO-704-01 CLINICAL COURSE OF PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY AWAY FROM TERTIARY REFERRAL CARE
25. PO-704-02 VAPING-ASSOCIATED SUDDEN DEATH IN THE YOUNG
26. PO-05-011 CLINICAL UTILITY OF PROTEIN LANGUAGE MODELS IN RESOLUTION OF VARIANTS OF UNCERTAIN SIGNIFICANCE IN KCNQ1, KCNH2, AND SCN5A COMPARED TO PATCH CLAMP FUNCTIONAL CHARACTERIZATION
27. PO-01-075 ROLE OF GENOTYPE IN RISK PREDICTION FOR ARRHYTHMOGENIC CARDIOMYOPATHIES
28. PO-01-188 A MULTI-OMIC COMPARISON OF SURGICAL MYECTOMY LEFT VENTRICULAR TISSUE REVEALS SEX-SPECIFIC DIFFERENCES IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
29. Red herring pathogenic variants: a case report of premature ventricular contraction-triggered ventricular fibrillation with an incidental pathogenic LMNA variant
30. Abstract 13342: Transcriptional Profiling of Surgical Myectomy Tissue in Patients With Hypertrophic Cardiomyopathy Reveals Genotype Independent Counterregulatory Alterations in Hypertrophy Pathways
31. Prevalence and Prognostic Significance of Hypertrophic Cardiomyopathy Phenotype in PKP2-Mediated Arrhythmogenic Cardiomyopathy.
32. B-PO05-190 ATHLETES WITH SUDDEN CARDIAC DEATH-PREDISPOSING GENETIC HEART DISEASE: WINNING THE ‘RETURN-TO-PLAY’ GAME
33. B-PO05-208 PATHOGENIC VARIANTS AS A RED HERRING: A CASE OF PREMATURE VENTRICULAR CONTRACTION-TRIGGERED VENTRICULAR FIBRILLATION WITH AN INCIDENTAL PATHOGENIC VARIANT IN LMNA-ENCODED LAMIN A/C
34. PO-03-143 PREVALENCE AND CLINICAL COURSE OF PEDIATRIC-ONSET ARRHYTHMOGENIC CARDIOMYOPATHY
35. BS-452759-1 SPATIAL CLUSTERING ANALYSIS HIGHLIGHTS DISEASE-SPECIFIC 3-DIMENSIONAL DISTRIBUTION OF PATHOGENIC VARIANTS IN THE SCN5A-ENCODED NAV1.5 CARDIAC SODIUM CHANNEL
36. BS-452758-3 SUPPRESSION-REPLACEMENT GENE THERAPY FOR LMNA-MEDIATED CARDIOMYOPATHIES
37. Failure to follow up on a medically actionable finding from direct to consumer genetic testing: A case report
38. Potential Health Risks Linked to Emerging Contaminants in Major Rivers and Treated Waters
39. PO-04-143 CARDIOVASCULAR OUTCOMES IN LMNA-MEDIATED CARDIAC LAMINOPATHY: THE MAYO CLINIC EXPERIENCE.
40. Temporal Association Between Vaping and Risk of Cardiac Events
41. Abstract 14269: The Association of Treadmill Exercise Test-Derived VO2Max and Symptomology in Athletes and Non-Athletes With Hypertrophic Cardiomyopathy
42. Abstract 14058: Clinical and Functional Reassessment of Alleged Type 5 Long QT Syndrome-Causative Genetic Variants in the KCNE1-Encoded Mink Beta-Subunit
43. A multi-omics atlas of sex-specific differences in obstructive hypertrophic cardiomyopathy.
44. Clinical Utility of Protein Language Models in Resolution of Variants of Uncertain Significance in KCNQ1, KCNH2 , and SCN5A Compared With Patch-Clamp Functional Characterization.
45. Histone Modifications and miRNA Perturbations Contribute to Transcriptional Dysregulation of Hypertrophy in Obstructive Hypertrophic Cardiomyopathy.
46. Red herring pathogenic variants: a case report of premature ventricular contraction-triggered ventricular fibrillation with an incidental pathogenic LMNA variant.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.